TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - BIOMARIN PHARMACEUTICAL Share Price

Certificat

DE000SV4FKJ3

Delayed Deutsche Boerse AG 18:35:30 29/05/2024 BST
5.31 EUR -0.75% Intraday chart for TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - BIOMARIN PHARMACEUTICAL
Current month+10.54%
1 month+11.92%
Date Price Change
29/05/24 5.31 -0.75%
28/05/24 5.35 +3.88%
27/05/24 5.15 -1.72%
24/05/24 5.24 -0.19%
23/05/24 5.25 +2.14%

Delayed Quote Deutsche Boerse AG

Last update May 29, 2024 at 06:35 pm

More quotes

Static data

Product typeKnock-Out without Stop Loss
Buy / SellPUT
Underlying BIOMARIN PHARMACEUTICAL INC.
IssuerLogo Issuer Société Générale Société Générale
WKN SV4FKJ
ISINDE000SV4FKJ3
Date issued 18/04/2023
Strike 131.5 $
Maturity Unlimited
Parity 10 : 1
Emission price 2.98
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 5.36
Lowest since issue 2.81
Spread 0.01
Spread %0.19%

Company Profile

BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.
Sector
-
More about the company

Ratings for BioMarin Pharmaceutical Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Consensus: BioMarin Pharmaceutical Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
74.43 USD
Average target price
109.3 USD
Spread / Average Target
+46.88%
Consensus